样式: 排序: IF: - GO 导出 标记为已读
-
Hypersensitivity reaction to Abiraterone, successful desensitization protocol in prostate cancer patient J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-15 Sandra N. González Díaz, Oscar Vidal Gutiérrez, José Carlos Rodríguez Román, Raquel A. López Henríquez, Carlos Macouzet Sánchez, Cindy E. de Lira Quezada, Natalhie Acuña Ortega
IntroductionIn prostate cancer, androgens are key in the growth of both normal prostate and cancer cells. Abiraterone acetate inhibits CYP17, an important target in prostate cancer given its central role in the production of adrenal and tumor-derived androgens. Although abiraterone is generally well tolerated, common adverse effects such as hypertension, hypokalemia, and hepatotoxicity have been reported
-
Medical cannabis use in oncology and associated outcomes: A scoping review J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-13 Ana Carolina Valente, Luis Phillipe Nagem Lopes, Maria Eline Matheus
BackgroundNatural and synthetic cannabinoids are being used worldwide to treat various symptoms in cancer patients. This study aims to map the therapeutic benefits and adverse effects associated with the use of cannabis-based drugs in these outcomes.MethodsFollowing Joanna Briggs Institute guidelines a scoping review was conducted. The study protocol was available in the Open Science Framework public
-
Antineoplastic agents associated with neutropenic enterocolitis in patients with malignancy: A quantitative safety signal analysis J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-13 Ali Amanati, Robbert Van Manen, Sarvin Sajedianfard, Hafez Shojaadini, Mohadese Boroughani, Hossein Molavi Vardanjani
BackgroundThe use of certain chemotherapy agents is associated with the development of a condition called “chemotherapy-associated neutropenic enterocolitis” (CANE).ObjectiveTo determine the risk of CANE associated with the use of each antineoplastic agent.MethodsThe FDA FAERS database of spontaneous adverse reactions was searched for the occurrence of the MedDRA preferred term “neutropenic colitis
-
Carboplatin desensitization – simplified 4-step 2-bag method J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-12 Polly E Kintzel, Gregory M Gressel, Brett T Van Rossum, Kristin N Hillaker, Lauren L Ice, Jacqueline J Eastman
IntroductionOur cancer program adopted a method for carboplatin desensitization (4-step 2-bag method) that administers the same intensity of drug exposure with a simplified approach to product management in comparison to a published protocol (4-step 4-bag method).MethodsThe intensity of carboplatin administration for 1:1,000, 1:100, 1:10, and 1:1 dilutions and concomitant fluid administration were
-
Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-12 Harshit Khosla, Sita Bhatt, Ming-Jin Wang, Gretchen Gignac, Kriti Mittal, Jasmine Patel
Enfortumab vedotin (EV) is a novel treatment option for patients with advanced/metastatic urothelial carcinoma who have progressed after chemotherapy and immunotherapy. Two patients at two different New England tertiary cancer care centers were treated with EV while concurrently receiving hemodialysis (HD), where a complete response to EV in both patients was noted. The use of EV in patients requiring
-
Oral anticancer medicine interventions: A cross-sectional study in French community pharmacies J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-08 Florent Macé, Christine Peyron, Amélie Cransac, Pauline Pistre, Mathieu Boulin
IntroductionThe increasing number of oral anticancer medicines (OAMs) dispensed in community pharmacies and the associated challenges (misuse, management of side effects) give the community pharmacist (CP) a major role in the pharmacotherapeutic management of cancer patients. In France, as a response to these challenges, cancer outpatients can schedule a meeting with their CP to ensure the safe and
-
Pharmacist's role in the management of drug–drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-08 Carlos Guzmán Cordero, María Sáez-Torres de Vicente, Álvaro Jiménez Espinosa, Ana Isabel Gago Sánchez
ObjectiveNew drugs developed for SARS-CoV-2 infection, such as nirmatrelvir/ritonavir (NMV/r), represent a potential for oncohematology patients, but also pose a challenge in managing the potential clinically relevant drug–drug interactions (pDDIs) that may arise. The aim of this study is to assess the frequency, severity, and pharmacist detection of pDDIs.MethodsThis prospective, observational, study
-
Selinexor for the treatment of patients with relapsed or refractory multiple myeloma J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-08 Anum Babar, Maham Babar, Hina Zubair, Arzu Shahid, Sana Rafique, Maimona Bano, Madeeha Subhan Waleed, Maimoona Khan, Arslan Inayat, Danish Safi
ObjectiveMultiple myeloma cells resist standard therapies due to overexpression of the transport protein, exportin 1. Selinexor is a novel drug that targets the Exportin 1 protein in these cells.Data sourceA comprehensive search was done, and data showing the efficacy and safety of selinexor in relapsed/refractory multiple myeloma was collected using PubMed, Google Scholar, and clincialtrials.gov.Data
-
Analysis of pharmaceutical interventions in chemotherapy prescriptions of adult and pediatric patients at an oncology reference institute J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-06 Rebeca Gripp de Sá Venancio, Erika da Silva Magliano, Elizangela Domiciano Garcia Barreto
Chemotherapy, one of the primary cancer treatments, has a high risk of causing significant harm in cases of its misuse. Pharmaceutical intervention is one of the strategies used to prevent medication errors from reaching the patient by identifying drug-related problems or other discrepancies related to patient data or medical progress. The primary objective of this study was to analyze the profile
-
Using simulation to improve pharmacy operators’ handling of cytotoxic spills J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-06 Alexandra Garnier, Pascal Bonnabry, Lucie Bouchoud
IntroductionInternational Society of Oncology Pharmacy Practitioners guidelines recommend having standard operating procedures (SOPs) and initial and yearly retraining programs on cytotoxic spill handling for pharmacy operators (POs). This study aimed to create a simulation-based training (SBT) program on this subject and evaluate its impact on POs’ real-life performance.MethodsRandomly formed pairs
-
Palonosetron in pediatric patients: A single-center, retrospective evaluation of policy and clinical practice guideline discordance J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-01 Meredith Ames, Priya Patel, L Lee Dupuis, Alicia Koo
IntroductionClinical practice guidelines (CPGs) recommending palonosetron for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) were adapted for use at our institution. Palonosetron was restricted for use in patients experiencing breakthrough CINV and receiving highly emetogenic chemotherapy (HEC) or undergoing stem cell transplant conditioning and in patients with refractory
-
Comparative study of dexamethasone premedication regimens with docetaxel chemotherapy in early HER-2 positive breast cancer: A safety net hospital experience J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-03-01 Avery Hager, Shreya Kondle, Amulya Agarwal, Monica Chintapenta, Rochelle Horadam, Navid Sadeghi, Samira Syed
IntroductionDocetaxel can cause fluid retention reactions (FRRs) and hypersensitivity reactions (HSRs). The manufacturer recommends a multi-day oral dexamethasone premedication to prevent these toxicities, but steroid related side effects and regimen compliance remain a concern. This study aimed to determine if modified dexamethasone premedication regimens resulted in differences in HSRs or FRRs to
-
Adhesive capsaicin 8% patch for improved control of pain caused by chemotherapy-induced peripheral neuropathy in patients with multiple myeloma: A single-centre, seven-case series J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-28 Deborah Moreno-Alonso, Sílvia Llorens-Torromé, Blanca Corcoy de Febrer, María Amandi García, Gala Serrano-Bermúdez, Jordi Trelis-Navarro, Victor Mayoral-Rojals, Ancor Serrano-Afonso
BackgroundCapsaicin is a highly selective agonist of the transient receptor potential vanilloid 1. The adhesive capsaicin patch provides a high capsaicin concentration (8%) directly in the painful area – its efficacy in benign peripheral neuropathic pain (diabetic neuropathy or postherpetic neuralgia) has recently been described in the literature. However, there is scant evidence of its efficacy in
-
Successful switch to cisplatin-based chemotherapy in a patient with lung cancer who developed a carboplatin-induced hypersensitivity reaction J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-26 Yuko Nagata, Gouji Toyokawa, Akiko Sugiyama, Shinichiro Shimamatsu, Ohki Saitoh, Hiroshi Okubo, Hitoshi Ueda
IntroductionPlatinum-based chemotherapy is the mainstay of first-line therapy for advanced-stage non-small cell lung cancer (NSCLC). Although carboplatin-induced hypersensitivity reactions (HSRs) commonly occur following multiple cycles of therapy, they are rarely observed during the first cycle of the treatment.Case reportHere, we report the case of a 70-year-old man with advanced-stage NSCLC who
-
Study to evaluate awareness about medication errors and impact of an educational intervention among healthcare personnel in a cancer hospital J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-26 Puskar Kunwor, Bijaya Basyal, Nabin Pathak, Pankaj Vaidya, Sudip Shrestha
IntroductionMedication errors (MEs) are preventable incidents that can result in harm to patients. Therefore, it is essential for healthcare professionals (HCPs) to be well-informed about MEs. This study aims to assess the awareness levels of HCPs and the impact of educational intervention on their understanding of MEs.MethodsResponses to a 17-question structured, self-administered questionnaire assessing
-
Assessment of potential drug–drug interactions in hospitalized cancer patients J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-26 Chameli Ratan, Mekha Rajeev, Karthik Krishnan, Hridya Jayamohanan, Niveditha Kartha, Meenu Vijayan, Keechilat Pavithran
IntroductionDrug–drug interactions (DDIs) pose a significant threat to patients with cancer, resulting in several adverse events in an oncology setting. Our study aims to identify potential DDIs in inpatient oncology wards, assess their severity, and provide recommendations to avoid these interactions.Materials and methodsThis prospective study was conducted in 79 hospitalized cancer patients over
-
Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-26 John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
ObjectiveDespite the relatively high cure rates in early-stage breast cancer, advanced and metastatic breast cancer cases are associated with more inauspicious patient outcomes. Fortunately, with the advent of cyclin-dependent kinase (CDK)4/6 inhibitors (e.g. palbociclib, ribociclib, and abemaciclib) with endocrine therapy, survival in advanced and metastatic breast cancer has appreciably improved
-
Revitalizing oncology medications access in Saudi Arabia: Current challenges and recommendations by the Saudi Oncology Pharmacy Assembly J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-20 Nora Alkhudair, Jude Howaidi, Mohammed Alnuhait, Majed Alshamrani, Mansour Khan, Atika Alharbi, Fouad Alnajjar, Eshtyag Bajnaid, Hajer Almodaheem, Mansour Alhowimel, Ali Alzahrani, Amr Khardaly, Mohammed Alnahedh, Hamdi Elsoudi, Hana Alabdulkareem, Ahmed Alrashidan, Musa Alzahrani, Abdullah Alrajhi
BackgroundCancer care is posing immense challenges to healthcare systems globally. Advances in screening, monitoring, and treating cancer improved patient outcomes and survival rates yet amplified the disease burden. Multiple barriers might impede early access to innovative therapies. We thoroughly examined the current challenges in oncology medication access in Saudi Arabia and provided consensus
-
Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-15 Jessie Lu, Bryan Do, Brian Primeaux
IntroductionSecond-generation Bruton's tyrosine kinase (BTK) inhibitors, acalabrutinib and zanubrutinib, are preferred agents for the treatment of relapsed and/or refractory mantle cell lymphoma (MCL) over first-generation BTK inhibitor, ibrutinib. The comparative safety and efficacy of these two agents have not been studied. Currently, the decision between using one second-generation BTK inhibitor
-
Evaluation of cost and infusion-related reactions among intravenous trastuzumab, subcutaneous trastuzumab, and trastuzumab biosimilars at an academic medical center J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-13 Daijah M Davis, Kasey Jackson, Christina Hoppe
IntroductionTrastuzumab is a vital treatment option for human epidermal growth factor 2 positive breast cancer. Since 2017, there have been 5 trastuzumab biosimilars approved for use. Despite hypotheses of infusion-related reactions among intravenous trastuzumab, subcutaneous trastuzumab, and trastuzumab biosimilars, there is minimal available literature comparing these agents. This evaluation will
-
Rechallenges without desensitization following platinum-based chemotherapy reactions J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-13 Fernanda D Young, Sidney Aung, Monica Tang, Karen M Anstey, Michael C Lee, Emely Alfaro, Pelin Cinar, Hansen Ho, Iris M Otani
BackgroundThere is increasing interest in non-desensitization protocols as a potential way to reintroduce chemotherapy following hypersensitivity reactions (HSR).ObjectiveTo provide insight into the potential utility of non-desensitization reintroduction, particularly at institutions where allergy consultation may not be available.MethodsFor 70 patients with platinum HSR who underwent rechallenge with
-
Manual versus automated chemotherapy preparation: A retrospective pharmaco-economic analysis J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-09 Meryem Chennaq, Soumaya El Baraka, Ali Cherif Chefchaouni, Houda Benahmed, Aicha Chaibi, Mohammed-Jaouad Belahcen, Younes Rahali
IntroductionThe National Oncology Institute of Morocco's (NIO) shift to an automated cytotoxic drug preparation system (PHARMODUCT®) has prompted an evaluation of its economic and clinical impacts compared to traditional manual methods.MethodsA retrospective cost-benefit analysis over six months, extrapolated to annual projections, assessed initial investments, labour, equipment, drugs and consumables
-
Pediatric oncology services in Nepal: A special focus on pharmacy practice J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-07 Shreya Dhungana, Nabin Pathak, Bijaya Basyal, Aman Kumar Sah, Anjali Pandit, Puskar Kunwor, Renu Karki
The role of clinical pharmacists or oncology pharmacists in pediatric oncology has been established as important in anticancer regimen review, dose calculation, recommendation, chemocounseling, identification of drug-related problems, its resolution, and, prevention and monitoring of adverse drug reactions within high-income countries. With several hospitals providing pediatric oncology services in
-
Real-world treatment outcomes from a retrospective cohort of patients with acute myeloid leukemia from an urban safety net hospital J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-02-07 Joseph P Marshalek, Raisa Epistola, Sarah Tomassetti
IntroductionWhile continual advancements in acute myeloid leukemia have augmented response rates and survival, outcomes in clinical trials may not correlate with real-world practice as trials may underrepresent individuals with comorbidities, decreased performance status, and older age. Additionally, clinical trials may underrepresent certain ethnicities, and disparities based on ethnicity, socioeconomic
-
Incidence of pulmonary toxicity in bleomycin-containing regimens for testicular cancer with and without the use of growth factor J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-31 Claire McAvoy, Paige Fields, Danielle Otto, Alexander Kreimer, Carleton S Ellis
IntroductionThe concurrent use of bleomycin and granulocyte colony-stimulating factors (G-CSFs) has historically been debated as a risk factor for bleomycin-induced pulmonary toxicity in patients with both testicular cancer and Hodgkin's lymphoma. The purpose of this study is to evaluate the incidence of pulmonary toxicity in patients with testicular cancer who were treated with bleomycin and pegfilgrastim
-
Concordance analysis of two databases to search for potential drug interactions in onco-hematologic patients J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-31 Pryscila Rodrigues Moreira, Leonardo Teodoro de Farias, Amanda Ribeiro Feitosa, Lunara Teles Silva, Tatyana Xavier Almeida Matteucci Ferreira, Mércia Pandolfo Provin, Rita Goreti Amaral, Ana Carolina Figueiredo Modesto
IntroductionPotential drug interactions exert a significant impact on patient safety, especially within intricate onco-hematological treatments, potentially resulting in toxicity or treatment failures. Despite the availability of databases for potential drug interaction investigation, persistent heterogeneity in concordance rates and classifications exists. The additional variability in database agreement
-
Pembrolizumab-induced agranulocytosis J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-31 Víctor Fernández Martínez, Adela García-Avello Fernández-Cueto, Carmen María Valencia Soto, Sara Barbadillo Villanueva, María Ochagavía Sufrategui, María Rioja Carrera, Lucía Andrea Alonso Buznego, Marta Valero Domínguez
IntroductionWith the widespread use of anti-programmed death-1 monoclonal antibodies, such as pembrolizumab, rare side effects appear in clinical practice.Case reportWe report the case of a man diagnosed with non-keratinizing squamous lung carcinoma stage IVB with programmed death-ligand 1 70% who developed agranulocytosis 10 days after a single dose of pembrolizumab as monotherapy.Management and
-
Incidence and severity of hand-foot syndrome in cancer patients receiving infusional 5-fluorouracil or oral capecitabine-containing chemotherapy regimens J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-24 Sulaikha Abdul Kareem, Simi Grace Joseph, Aneena Wilson, Shahnaz Abdul Kareem, Jobin Kunjumon Vilapurathu
BackgroundHand-foot syndrome is a common adverse effect of 5-fluorouracil infusion or oral capecitabine. Several types of research have shown that clinical presentations of hand-foot syndrome vary by ethnicity, so we tried to look at the incidence and severity of hand-foot syndrome in individuals receiving infusional 5-fluorouracil or oral capecitabine at a tertiary care hospital in central Kerala
-
The risk of pocket infection or bloodstream infection following central venous port placement for the patients with Cetuximab therapy J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-23 Shintaro Sueyoshi, Takeharu Ono, Shun-ichi Chitose, Mioko Fukahori, Takashi Kurita, Hirohito Umeno
ObjectiveCetuximab is a molecular targeted drug that targets epithelial growth factor receptors. The skin toxicity of cetuximab arising from epithelial growth factor inhibition is well known. Some patients with cetuximab therapy decided to make central venous port during the long-term intravenous treatments. Therefore, the author hypothesized that cetuximab administration might increase the risk of
-
Successful desensitization in a patient with recurrent anaplastic oligodendroglioma presenting with procarbazine-mediated anaphylaxis J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-23 Hazal Kayikçi, Özge Can Bostan, Gülseren Tuncay, Melek Cihanbeylerden, Çise Tüccar, Ebru Damadoglu, Gül Karakaya, Ali Fuat Kalyoncu
IntroductionProcarbazine is an oral chemotherapeutic agent used in the treatment of brain malignancies and is associated with hypersensitivity reactions. In case of grade 4 reactions, rechallenge should be avoided, and the agent should be replaced, unless the treatment is curative, in which case the application of a desensitization protocol should be considered. We present a successful case of desensitization
-
Hyperammonemic encephalopathy after tyrosine kinase inhibitors: A literature review and a case example J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-23 Héctor Carlos García-Díaz, Simeon Eremiev, Javier Gómez-Alonso, Joel Veas Rodriguez, Anna Farriols, Maria J Carreras, César Serrano
ObjectiveTo review the evidence of uncommon but fatal adverse event of hyperammonemic encephalopathy by tyrosine kinase inhibitors (TKI) and the possible mechanisms underlying this condition and to describe the case of a patient that developed drug-induced hyperammonemic encephalopathy related to TKI.Data SourcesLiterature search of different databases was performed for studies published from 1 January
-
Chemotherapeutic metabolism presenting as a recalcitrant case of hand–foot syndrome and mucositis J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-11 Kevin R Kwan, Shayna Skokan, Tara Blesh-Boren, Jenilee Vogel, Nicole Harter, James B Ford
IntroductionMercaptopurine (6MP) and methotrexate (MTX) are commonly used for maintenance chemotherapy for acute lymphoblastic leukemia (ALL). These medications have been associated with various side effects such as myelosuppression, colitis, and thyroiditis in addition to numerous cutaneous adverse events. Cutaneous side-effects most reported include mucositis, alopecia, xerosis, and pruritus. We
-
Innovative strategies for effective paclitaxel delivery: Recent developments and prospects J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-11 Sławomir Wileński, Agnieszka Koper, Paulina Śledzińska, Marek Bebyn, Krzysztof Koper
PurposePaclitaxel is an effective chemotherapeutic agent against a variety of cancer types. However, the clinical utility of paclitaxel is restricted by its poor solubility in water and high toxicity, resulting in low drug tolerance. These difficulties could be resolved by using suitable pharmacological carriers. Hence, it is essential to determine innovative methods of administering this effective
-
Correlation analysis of EGFR gene mutation abundance and the efficacy of targeted therapy with osimertinib in nonsmall cell lung cancer—a case control study J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-10 Haiqiang Yan, Jigui Peng, Wang Zhou, Hui Chen, Changjin He
BackgroundIn nonsmall cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) mutation is the primary cancer-causing mutation. But whether the practical effectiveness of EGFR tyrosine kinase inhibitors (TKIs) can be influenced by plasma EGFR mutation abundance when treating patients with advanced NSCLC remains unanswered. Therefore, this research was intended to reveal the connection between
-
Clinical significance of coadministration of moderate to strong CYP enzyme inhibitors with doxorubicin in breast cancer patients receiving AC chemotherapy J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-10 Amy Priest Dawson, Chrissy D Frick, Megan Burd, Brette Conliffe
IntroductionCytochrome P450 (CYP) enzyme inhibitors may increase the toxicity of many chemotherapies. Medication databases classify doxorubicin coadministration with CYP2D6 or CYP3A4 inhibitors as either a major interaction or contraindication. This study assessed the incidence of toxicity secondary to doxorubicin given with or without CYP enzyme inhibitors in breast cancer patients receiving doxorubicin
-
Incidence of immune-related adverse events in U.S. veterans treated with immune checkpoint inhibitors J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-09 Courtney Krall, Marshall Tague, Brian C Lund
BackgroundImmune checkpoint inhibitors (ICIs) are associated with potentially severe immune-related adverse events (irAEs). Emerging clinical practice reports have suggested higher incidence of irAEs in real-world settings than initially observed in phase III clinical trials. Objectives were to determine the incidence of irAEs associated with ICIs in a clinical population, the Veterans Health Administration
-
Assessing the effectiveness of gabapentin in paclitaxel-induced arthralgia, myalgia, and neuropathic pain: An observational, cohort study J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-05 Prashantkumar Patel, Hemraj Singh Rajput, Khushboo Chavda, Smit Mistry, Sandesh Bhagat, Rajesh Hadia, Moinuddin Saiyed, Avinash Khadela
Background and objectivesArthralgia, myalgia, and neuropathic pain are the most common side effects observed due to paclitaxel chemotherapy. The aim of this study was to investigate the prophylactic role, maintenance, remission, and re-occurrence of arthralgia, myalgia, and neuropathic pain post-gabapentin therapy.MethodologyThis study was conducted in the Department of Oncology, Dhiraj Hospital, Vadodara
-
Impact of age, obesity, and renal impairment on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-03 Kelly J Gaffney, Jonathan K. Bakos, Arash Velayati, James A. Davis, Aswani Thurlapati, Erin Weeda, Andy Maldonado, Katelynn Granger, Coleen Butcher, Taylor Herrington, Deidra Smith, Kimberly Green, Brian T Hess, Hamza Hashmi
IntroductionThere remains a need to determine whether certain subgroups of newly diagnosed multiple myeloma (NDMM) derive the same benefit from high-dose chemotherapy–autologous stem cell transplant (HDT-ASCT). We describe our institutional experience highlighting the impact of age, obesity, and renal impairment on outcomes after HDT-ASCT for patients with NDMM in a real-world setting.MethodsA total
-
Patterns of interventions for central venous catheter-associated deep vein thrombosis and outcomes in cancer patients J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2024-01-03 Dat Ngo, Jason Chen, Chris Nguyen, Kathy Choi, Vinod Pullarkat
PurposeThis letter evaluated the impact of different management strategies, specifically the presence or absence of therapeutic anticoagulation, on clinical outcomes for central venous catheter (CVC)-associated deep vein thrombosis (DVT) in cancer patients.MethodsOne-hundred ninety-eight adult cancer patients with a confirmed CVC-associated DVT diagnosis from February 2013 and February 2021 were included
-
A review and metanalysis of metronomic oral single-agent cyclophosphamide for treating advanced ovarian carcinoma in the era of precision medicine. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-28 Federica Martorana,Giuseppina Scandurra,Maria Rosaria Valerio,Salvatore Cufari,Paolo Vigneri,Maria Vita Sanò,Giuseppe Scibilia,Paolo Scollo,Vittorio Gebbia
OBJECTIVE Oral metronomic cyclophosphamide has been used as a single agent or in combination with other drugs for several solid tumors with interesting results in disease palliation and mild to moderate toxicity, notably in patients with recurrent epithelial ovarian cancer (EOC) progressing after systemic chemotherapy. In this paper, we report a review and a metanalysis of heterogeneous data published
-
National survey of safe handling of hazardous drugs in hospital settings: Use of an innovative approach. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-24 Emma Pinet,Annie Langlais,Audrey Chouinard,Jean-François Bussières,Cynthia Tanguay
INTRODUCTION Workers can reduce their risk of exposure to hazardous drugs by following safe handling guidelines. Healthcare centers need to dedicate time and resources in order to implement new safety recommendations. The objective was to present the results of a national survey about the safe handling of hazardous drugs in healthcare centers. METHODS Quebec healthcare centers performed an auto-evaluation
-
Outcomes of weight-based vs. fixed dose of Pembrolizumab among patients with non-small cell lung cancer. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-21 Lena Chaitesipaseut,Nina Shah,Thach-Giao Truong,Fang Niu,Patrick Shin,Kavita Sharma,Joshua Smith,Rita L Hui
OBJECTIVE This study aims to assess outcomes among patients with non-small cell lung cancer (NSCLC) who received treatment with pembrolizumab on a weight-based dose (WBD) or fixed-dose (FD) regimen using a non-inferiority (NI) analysis. MATERIAL AND METHODS This retrospective cohort study included adult patients with NSCLC weighing under 100 kg who received pembrolizumab between 1 January 2015 and
-
Successful use of split-dose intravenous daratumumab in a multiple myeloma patient after a first-dose life-threatening infusion-related reaction. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-21 Fatma Aykaş,Volkan Karakuş,Ömür Gökmen Sevindik
INTRODUCTION Daratumumab is a humanized IgG1 kappa monoclonal antibody directed against CD38 used to treat myeloma. The recommended dose of daratumumab is 16 mg/kg, with no lower or upper threshold. Here, we present the first split-dose daratumumab infusion experience in a myeloma patient with morbid obesity in whom daratumumab was interrupted because of grade 3 infusion-related reaction. CASE REPORT
-
Hypercalcemia associated with interaction between all trans retinoic acid and fluconazole in an acute promyelocytic leukemia and acquired hypoparathyroidism case. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-19 Büşra Tuğçe Akman,Deniz Arıca,Ebru Koca,Sema Karakuş
INTRODUCTION Acute promyelocytic leukemia (APL) is the most malignant form of acute myeloid leukemia (AML) with short survival without treatment. All trans retinoic acid (ATRA) is a vitamin A metabolite and plays an important role in the treatment of APL. Hypercalcemia is a rare side effect of ATRA. CASE REPORT A 67-year-old female patient was investigated due to widespread bruising and pancytopenia
-
Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-19 Emma F Lodl,Mohammad H Alshaer,C Brooke Adams,Ashley Richards,Charles Peloquin,Veena Venugopalan
INTRODUCTION Cefepime is a fourth-generation cephalosporin and is a workhorse for the empiric treatment of febrile neutropenia (FN). Beta-lactam therapeutic drug monitoring (TDM) has emerged as a dose optimization strategy in patient populations with altered kinetics. Prior literature has demonstrated that patients with FN exhibit augmented renal clearance which may lead to subtherapeutic drug concentrations
-
Unusual encephalopathy with Wernicke-Korsakoff syndrome-like features due to adjuvant nivolumab for malignant melanoma. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-19 Saniya Malik,Wendy White,Constantin A Dasanu
INTRODUCTION Autoimmune encephalitis is a rare immune-related adverse event of PD-1 inhibitors, nivolumab and pembrolizumab. Autoimmune hypophysitis can also be seen with the use of these agents. The relationship between these two phenomena is currently unknown. CASE REPORT We describe a 79-year-old man with anterior scalp melanoma who received adjuvant nivolumab therapy. Sixteen weeks after the completion
-
Relative dose intensity of taxane-based chemotherapy in breast cancer patients in a tertiary hospital. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-15 Amira M Helwani,Yousuf M Al Suleimani,Khalid Al Baimani,Aly M Abdelrahman
INTRODUCTION Breast cancer (BC) is the most diagnosed tumor among women worldwide. The aim of this study was to investigate the incidence and causes of low relative dose intensity (RDI) < 85% for taxane-based chemotherapy regimens used in the treatment of BC in Sultan Qaboos University Hospital (SQUH). METHODS This was a retrospective study that included 303 BC patients, treated with taxane-based chemotherapy
-
Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-13 Samantha E Clark,Zachary A Marcum,Jerry Radich,Ruth Etzioni,Anirban Basu
INTRODUCTION Adherence to imatinib in chronic myeloid leukemia (CML) patients is estimated to be as low as 70% despite its clinical benefit, and our understanding of the impact of nonadherence in this population is limited. This study presents a novel application of the Alternating Conditional Estimation (ACE) algorithm in newly diagnosed CML patients to map the full dose-response curve (DRC) and determine
-
BOPA launches a new Digital SACT Verification Passport. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-13 Netty Cracknell
-
Acute infusion-related reactions in pediatric patients receiving etoposide at a tertiary cancer center. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-13 Patrick McBride,Barbara Degar
INTRODUCTION Etoposide is a key component of many pediatric chemotherapy regimens for both hematologic and solid tumors. It is well documented that patients receiving etoposide may experience infusion-related reactions. METHODS In this study, total doses of etoposide and etoposide phosphate were identified, and infusion-related reactions were retrospectively evaluated at a large pediatric oncology
-
Patterns of prescription opioid use and opioid-related harms among adult patients with hematologic malignancies. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-09 Nadia A Nabulsi,Lisa K Sharp,Karen I Sweiss,Pritesh R Patel,Gregory S Calip,Todd A Lee
INTRODUCTION Treatment advances for hematologic malignancies (HM) have dramatically improved life expectancy, necessitating greater focus on long-term cancer pain management. This study explored real-world patterns of opioid use among patients with HM. METHODS This retrospective cohort study identified adults diagnosed with HM from January 1, 2013 through December 31, 2019 using the Truven MarketScan
-
Premedication strategy in cetuximab rechallenge after Grade 2 hypersensitivity reactions. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-08 Molly Lofy,Lindsey Jung,Elizabeth Dow-Hillgartner
INTRODUCTION Cetuximab, an IgG1 monoclonal antibody, is utilized in the treatment of metastatic colorectal cancer and squamous cell head and neck cancers. Due to the risk of hypersensitivity reactions, standard premedication with a histamine-1 (H-1) antagonist is recommended prior to administration, however, there is less guidance for premedication strategies to assist with rechallenge after infusion
-
Optimizing antimicrobial prophylaxis strategies in acute leukemia patients: Assessing the efficacy of fluconazole. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-07 Nicholas S Teran,Grace S Park
BACKGROUND Acute myeloid (AML) and promyelocytic (APL) leukemia patients are at high risk for infection and mortality. While guidance for infection prevention is provided by the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO), each institution may vary in antimicrobial prophylaxis prescribing practices. The discrepancy may be explained by medication
-
Rapid drug desensitization to taxanes: a descriptive study from Turkey. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-07 Selma Yeşilkaya,Kurtuluş Aksu,Gürgün Tuğçe Vural Solak,Şenay Demir,Musa Topel,Dilek Çuhadar Erçelebi,İlkay Koca Kalkan,Hale Ateş,Gözde Köycü Buhari,Sakine Nazik Bahçecioğlu
AIM To present the characteristics of drug hypersensitivity reactions (DHRs) among taxane recipients with non-small cell lung carcinoma (NSCLC), and to describe the results of rapid drug desensitization (RDD). METHODS A retrospective cross-sectional study included 45 patients who were treated with taxane for NSCLC and were found to be hypersensitive to taxane. All patients were administered the standard
-
Impact of relative dose intensity on pathologic complete response in human epidermal growth factor receptor 2 positive breast cancer patients receiving neoadjuvant TCHP. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-07 Kaylyn Collette,Cassandra L Perkey,Val Adams,Brent J Shelton,Lauren S Corum,Allison Butts
PURPOSE The standard of care for locally advanced, human epidermal growth factor receptor 2 positive (HER2+) breast cancer includes neoadjuvant chemotherapy with docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP). Many patients do not receive the full course of therapy due to various complications, possibly affecting the potential to achieve a pathologic complete response (pCR). The amount
-
Use of antithymocyte globulin (rabbit) in a patient with known alpha-gal syndrome undergoing allogenic stem cell transplantation. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-11-07 Hannah Peterson,Drew A Wells,Dennis Marjoncu,Kori Holman
INTRODUCTION Alpha-gal syndrome (AGS) is a hypersensitivity disorder in which tick bites-most commonly from the lone star tick (Ambylomma americanum)-trigger immunoglobulin E-mediated hypersensitivity reaction upon exposure to oligosaccharide galactosse-alpha-1,3-galactose (α-gal). α-gal is most notorious for being found in "red meat" products but is present in mammalian meats such as beef, pork, lamb
-
Development of oral oncolytic nonadherence estimator (ORACLE): A pretreatment nonadherence risk assessment for oral oncolytics. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-10-30 Jessie Signorelli,Thuy Tran,Marie E Sirek,Yarelis Díaz-Rohena,Jodi L Taraba,Benyam Muluneh,Nayanika Basu,Jennifer Lilly,Julianne Darling
INTRODUCTION To date, there is no adherence estimator to identify risk of nonadherence prior to initiating oral oncolytics. METHODS A workgroup was assembled through the National Community Oncology Dispensing Association and tasked with creating a tool to meet this need. Tool constructs were defined after a review of the literature identifying top barriers to adherence. A second literature search was
-
Liver toxicity with ribociclib in a patient with metastatic hormone receptor positive postmenopausal breast cancer. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-10-30 Sumru Sozer Karadagli,Pınar Gursoy
INTRODUCTION In recent years, highly selective reversible CDK4/6 inhibitors have been combined with aromatase inhibitors for their efficacy and ease of application in the treatment of advanced stage of hormone-responsive breast cancers. Oral use of these drugs facilitates patient compliance. However, adverse drug reactions are reported due to these drugs, in the literature. Diverse adverse reactions
-
Real world practices of luspatercept at an academic medical center. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-10-30 Madison Koons,Jessie R Signorelli,Chris Bell,Brenna Rowen
Introduction: Luspatercept is approved for patients with very low-to intermediate-risk myelodysplastic syndrome (MDS). Dosing is based on pre-dose hemoglobin levels and transfusion requirements. This study aims to evaluate if a site with a pharmacist prospectively reviewing luspatercept doses achieves dose optimization, compared to a site that does not have a pharmacist prospectively reviewing doses
-
Elotuzumab: Empiric analysis of dexamethasone administration schedule. J. Oncol. Pharm. Pract. (IF 1.3) Pub Date : 2023-10-25 Polly E Kintzel
Elotuzumab in combination with dexamethasone and immunomodulating agents (IMiDs) lenalidomide or pomalidomide is 2nd to 4th line therapy for multiple myeloma. The labelled dosage of dexamethasone for use in conjunction with elotuzumab and IMiDs splits the dexamethasone dose into two administrations, one oral and one intravenous, on the days of each elotuzumab infusion. Administration of split dose